Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03715455 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-03715455 | EXPERIMENTAL | - |
| PH-797804 | EXPERIMENTAL | - |
| Placebo for PF-03715455 | PLACEBO_COMPARATOR | - |
| Placebo for PH-797804 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-03715455 | DRUG | 20mg, Inhaled, single dose |
| PH-797804 | DRUG | 30mg, Oral, single dose |
| Placebo for PF-03715455 | DRUG | Single dose, inhaled, Placebo for PF-03715455 |
| Placebo for PH-797804 | DRUG | Single Dose, Oral, Placebo for PH-797804 |
Inclusion Criteria: * Male or female (of non-child bearing potential) subjects, aged 18-50 years. * Subjects whose FEV1 and FVC at screening are both greater than or equal to 80% of their predicted value for age, race, sex and height. * Subjects who have normoresponsive airways. * Subjects who are ...
PF-03715455 is an investigational small molecule drug that Pfizer, Inc. (ticker PFE) developed for Chronic Obstructive Pulmonary Disease (COPD), a respiratory condition. It was studied in a Phase 1 clinical trial and is not an approved medicine. Development reached the early clinical stage only.
PF-03715455 was being developed for Chronic Obstructive Pulmonary Disease (COPD), a respiratory condition. Its only recorded clinical study enrolled healthy adult volunteers rather than COPD patients, and it was designed as a single dose study. The drug is investigational and is not approved for treating COPD or any other condition.
PF-03715455 targets MAPK14, also known as p38 alpha, and acts as an inhibitor of that enzyme. MAPK14 is a kinase involved in inflammatory signaling pathways. Inhibiting MAPK14 was the intended mechanism for addressing the inflammatory component of Chronic Obstructive Pulmonary Disease (COPD).
PF-03715455 was developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the compound's clinical program in respiratory disease. The asset is an internal Pfizer small molecule and reached Phase 1 testing before the program's recorded study was completed.
PF-03715455 reached Phase 1 clinical development. It is an investigational drug and is not FDA approved. Its single recorded trial, NCT01314885, is completed, and no active trials are listed for the compound. The program therefore sits at the earliest stage of human testing.
PF-03715455 was studied in one clinical trial, NCT01314885, titled Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers. The Phase 1 trial was completed, enrolled 39 healthy adult participants in the United Kingdom, and used a randomized, double-blind, placebo-controlled design. No other trials of PF-03715455 are recorded.